Welcome to our dedicated page for ImmunityBio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio, Inc. (IBRX) 10-Q — Quarter ended June 30, 2025: Condensed consolidated assets totaled $402,076 as of June 30, 2025, including $137,658 cash and cash equivalents, $16,000 marketable securities and $22,126 accounts receivable. Total current assets were $208,132. Major non‑current assets include PP&E net $133,004 and goodwill/intangibles net $14,977. Total liabilities were $971,895, driven notably by a $492,084 related‑party convertible note payable and a $307,049 revenue interest liability; warrant liabilities were $66,957. Stockholders' deficit was $(570,749).
Operating results and cash flows: Product revenue increased to $26,421 for Q2 2025 (Q2 2024: $990) and $42,930 for six months 2025 (six months 2024: $990). Loss from operations was $(71,285) for Q2 and $(135,714) for six months; net loss was $(92,574) for Q2 and $(222,240) for six months. Net cash used in operating activities for the six months was $(165,651). The company discloses an accumulated deficit of $3.6 billion and states substantial doubt about going concern without additional funding, though management cites expected support from the Founder and other sources.
ImmunityBio (IBRX) filed an 8-K disclosing a capital raise. On 24 Jul 2025 the company executed a Securities Purchase Agreement to sell 29,629,632 common shares together with five-year warrants for an equal number of shares. Each share-and-warrant unit is priced at $2.70, while the warrants carry a $3.24 exercise price and become immediately exercisable. Gross proceeds are expected to be about $80 million before fees and expenses; closing is targeted for 28 Jul 2025 subject to customary conditions.
Piper Sandler & Co. will act as exclusive placement agent under a separate agreement and will receive a cash fee equal to 6.0 % of gross proceeds (no fee on warrant exercises). The securities are being issued from the company’s effective shelf registration statement on Form S-3ASR.
The 8-K also references two press releases dated 25 Jul 2025: (i) a business update with preliminary, unaudited Q2 results and regulatory developments, and (ii) an announcement of the registered direct offering. Full financial figures were not included in the filing; exhibits provide the SPA, warrant form, placement agency agreement, legal opinion and related consents.
ImmunityBio has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, a large accelerated filer based in San Diego, is led by CEO Richard Adcock and Executive Chairman Patrick Soon-Shiong, who serves as Global Chief Scientific and Medical Officer.
Key aspects of the filing include:
- Registration of securities for employee benefit plan purposes
- Incorporation of recent financial documents including 2024 Annual Report and Q1 2025 quarterly report
- Comprehensive indemnification provisions for directors and officers
- Strong corporate governance structure with Cheryl L. Cohen serving as Lead Independent Director
The filing includes standard undertakings required by the SEC, including commitments to file post-effective amendments when necessary and provisions regarding indemnification. The registration is supported by legal opinion from Wilson Sonsini Goodrich & Rosati and includes required consents from independent auditors.
ImmunityBio director Christobel Selecky received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative securities transaction details include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs at earlier of June 18, 2026 or day before next annual stockholder meeting
- Vesting conditional on continuing service as defined in 2025 Equity Incentive Plan
This represents a standard annual director equity compensation grant. The filing was signed by Jason Liljestrom as attorney-in-fact on June 20, 2025. The options are held directly by the reporting person with no indirect beneficial ownership reported.
ImmunityBio director Cheryl Cohen received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs on the earlier of June 18, 2026 or the day before the next annual stockholder meeting
- Vesting is contingent on continued service as defined in the 2025 Equity Incentive Plan
This grant represents standard director compensation and was filed by Jason Liljestrom as attorney-in-fact on June 20, 2025. The ownership form is listed as Direct (D), indicating Cohen holds these options personally rather than through any indirect arrangement.
ImmunityBio (IBRX) director Michael D. Blaszyk received a stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% of shares vest on the earlier of June 18, 2026 or the day before the next annual stockholder meeting
- Vesting is contingent on Blaszyk remaining a Service Provider under the company's 2025 Equity Incentive Plan
This Form 4 filing represents a standard director compensation equity grant, suggesting continued board engagement and alignment with shareholder interests through long-term equity incentives.
ImmunityBio director Linda Maxwell received a stock option grant on June 18, 2025, representing a significant insider transaction. The details include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs at earlier of June 18, 2026 or day before next annual stockholder meeting
- Vesting conditional on continued service as defined in 2025 Equity Incentive Plan
This Form 4 filing represents standard board of director equity compensation. The direct ownership structure and 10-year option term align with typical corporate governance practices for director incentivization.
ImmunityBio director Wesley Clark received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative securities transaction details include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs at earlier of June 18, 2026 or day before next annual stockholder meeting
- Vesting conditional on continued service as defined in 2025 Equity Incentive Plan
The filing indicates direct ownership of these options by Clark, who serves as a Director of ImmunityBio. This equity compensation grant aligns with standard board member compensation practices and aims to align the director's interests with shareholders.
ImmunityBio, Inc. (NASDAQ: IBRX) filed an 8-K to report the results of its 2025 Annual Meeting held on 18 June 2025 and the adoption of a new share-based compensation program.
Equity Incentive Plan: Stockholders approved the 2025 Equity Incentive Plan, which immediately replaces the 2015 plan scheduled to expire in July 2025. The new plan reserves 46,088,027 new shares of common stock and allows recycling of up to 32,359,674 shares from previously granted but forfeited or expired awards under the 2015 plan. In total, up to roughly 78 million shares (≈ 8.8 % of shares outstanding) could be issued over time, subject to customary anti-dilution adjustments.
Governance Matters: • A strong quorum was achieved with 785,427,063 shares (≈ 89 % of outstanding) represented.
• All eight incumbent directors—including Executive Chairman Patrick Soon-Shiong, M.D.—were re-elected. “For” votes ranged from 695.2 million to 700.9 million, with minimal opposition and 81.7 million broker non-votes.
• The 2025 Equity Incentive Plan garnered 684.0 million votes “For” (≈ 96 % of votes cast, excluding broker non-votes).
• Deloitte & Touche LLP was ratified as auditor for fiscal 2025 with 781.3 million votes “For” (≈ 99 %).
Strategic Rationale: The Board states the new plan is intended to enhance ImmunityBio’s ability to attract, retain, and motivate key talent by providing equity-based incentives that align employee and shareholder interests. No additional awards will be granted under the 2015 plan, but existing awards will continue to be governed by it.
No financial performance metrics, earnings data, or major transactions were disclosed in this filing. The only exhibit filed is the full text of the 2025 Equity Incentive Plan (Exhibit 10.1).